Stocks and Investing Stocks and Investing
Tue, May 10, 2022

Gena Wang Maintained (ARCT) at Sell with Decreased Target to $17 on, May 10th, 2022


Published on 2024-10-27 20:58:40 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Maintained "Arcturus Therapeutics Holdings Inc." (ARCT) at Sell with Decreased Target from $21 to $17 on, May 10th, 2022.

Gena has made no other calls on ARCT in the last 4 months.



There are 3 other peers that have a rating on ARCT. Out of the 3 peers that are also analyzing ARCT, 1 agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Steven Seedhouse of "Raymond James" Upgraded from Sell to Hold on, Monday, January 31st, 2022


These are the ratings of the 2 analyists that currently disagree with Gena


  • John Abbott of "Wells Fargo" Maintained at Buy with Decreased Target to $105 on, Friday, March 25th, 2022
  • Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $86 on, Tuesday, March 15th, 2022
Contributing Sources